Vestaron Corporation Promotes Robert Kennedy to Chief Scientific Officer
News Jan 23, 2012
In so doing, Dr. Kennedy will continue to report to Steven Hartmeier, President and CEO.
Dr. Kennedy has served as Vice President of Research at Vestaron for the past three years, and has led the team to an anticipated registration filing with the EPA of its first product at the end of this first quarter. Dr. Kennedy's prior experience includes scientific leadership positions at Pfizer, Parke-Davis, American Cyanamid and an academic appointment at Columbia University. Dr. Kennedy also currently serves as an adjunct Associate Professor in the School of Pharmacy at the University of Michigan.
"Vestaron is the leader in the of development of venom peptides for biorational insect control," said Dr. Kennedy. "I am excited about the progress of our peptide product development programs and also our grant for the development of synthetic insecticides for the control of malarial vectors through the Foundation for the National Institutes of Health. I look forward to working with my colleagues to continue to advance our technology platform and contribute to the success of the company."
"Over the past several years, Dr. Kennedy has provided outstanding scientific leadership to the technical team across the company's GMO, peptide and synthetic product development streams. He has assumed broad responsibilities in our company, with a strong track record of success. He is a well-respected scientific leader in whom I have great confidence, and therefore I am pleased to announce this expansion of his role at Vestaron," noted CEO Steven Hartmeier.